Medicinova INC (MNOV) — SEC Filings

Overview

Medicinova INC (MNOV) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 30, 2025: On December 29, 2025, MEDICINOVA, INC. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in La Jolla, CA, filed this 8-K report to disclose this event. The filing also includes financial statements and exhibits.

Sentiment Summary

Across 17 filings, the sentiment breakdown is: 3 bearish, 14 neutral. The dominant filing sentiment for Medicinova INC is neutral.

Filing Type Overview

Medicinova INC (MNOV) has filed 6 8-K, 6 10-Q, 1 S-1, 2 DEF 14A, 2 10-K with the SEC between Feb 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (17)

• MEDICINOVA, INC. Files 8-K for Material Definitive Agreement — 8-K · Dec 30, 2025 Risk: medium
  On December 29, 2025, MEDICINOVA, INC. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices
• MediciNova's Q3 Loss Widens Amid Increased R&D Spend — 10-Q · Nov 12, 2025 Risk: high
  MediciNova, Inc. (MNOV) reported a net loss of $3,050,373 for the three months ended September 30, 2025, an increase from a net loss of $2,852,179 for the same
• MediciNova Files S-1 for 25M Share Offering by YA II PN, LTD. — S-1 · Aug 22, 2025 Risk: high
  MediciNova, Inc. (MNOV) is offering up to 25,000,000 shares of common stock through a selling stockholder, YA II PN, LTD., under a Standby Equity Purchase Agree
• MediciNova's Losses Widen Amid Increased R&D Spend — 10-Q · Aug 14, 2025 Risk: high
  MediciNova, Inc. (MNOV) reported a net loss of $3,281,185 for the three months ended June 30, 2025, a 24.8% increase from the $2,628,200 net loss in the same pe
• Medicinova Inc. Files 8-K for Material Definitive Agreement — 8-K · Aug 1, 2025 Risk: medium
  On July 30, 2025, Medicinova, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in L
• MEDICINOVA, INC. Files 8-K on Security Holder Vote Matters — 8-K · Jun 18, 2025 Risk: low
  On June 17, 2025, MEDICINOVA, INC. filed an 8-K report to announce the submission of matters to a vote of its security holders. The filing details the company's
• MedicinoVa Inc. Files Q1 2025 10-Q Report — 10-Q · May 13, 2025 Risk: low
  MedicinoVa Inc. filed its quarterly report for the period ending March 31, 2025. The company, located at 4275 Executive Square, Suite 300, La Jolla, CA 92037, r
• MedicinoVa Files 2025 Proxy Statement — DEF 14A · Apr 28, 2025 Risk: low
  MedicinoVa, Inc. filed its definitive proxy statement (DEF 14A) on April 28, 2025, for its annual meeting scheduled for June 17, 2025. The filing provides detai
• MEDICINOVA INC Files 8-K Report — 8-K · Mar 11, 2025 Risk: low
  On March 11, 2025, MEDICINOVA INC filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific
• MediciNova Files 2024 10-K — 10-K · Feb 19, 2025 Risk: medium
  MediciNova Inc. filed its 2024 10-K on February 19, 2025, reporting on its fiscal year ending December 31, 2024. The company, incorporated in Delaware and headq
• MedicinoVa Inc. Files Q3 2024 10-Q Report — 10-Q · Nov 13, 2024 Risk: low
  MedicinoVa Inc. reported its third-quarter results for the period ending September 30, 2024. The company's filing details its financial position and operational
• MEDICINOVA INC. Files Q2 2024 10-Q Report — 10-Q · Aug 8, 2024 Risk: low
  MEDICINOVA INC. filed its 10-Q for the period ending June 30, 2024. The company's fiscal year ends on December 31st. Key financial data points and equity incent
• MEDICINOVA INC Files 8-K on Security Holder Vote Matters — 8-K · Jun 12, 2024 Risk: low
  On June 11, 2024, MEDICINOVA INC filed an 8-K report indicating a submission of matters to a vote of security holders. The filing details the company's corporat
• MEDICINOVA INC Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: medium
  MEDICINOVA INC (MNOV) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. MEDICINOVA INC filed a 10-Q report for the period ending March 31, 2024. The
• MediciNova, Inc. Announces 2024 Annual Meeting of Stockholders on June 11, 2024 — DEF 14A · Apr 26, 2024 Risk: low
  MEDICINOVA INC (MNOV) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. MediciNova, Inc. will hold its 2024 Annual Meeting of Stockholders on Ju
• MEDICINOVA INC Reports Board and Officer Changes — 8-K · Apr 1, 2024 Risk: medium
  On March 26, 2024, MEDICINOVA, INC. filed an 8-K report detailing changes in its board of directors and executive officers. The filing indicates the departure o
• MEDICINOVA INC Files 10-K for Fiscal Year Ended December 31, 2023 — 10-K · Feb 15, 2024 Risk: medium
  MEDICINOVA INC (MNOV) filed a Annual Report (10-K) with the SEC on February 15, 2024. MEDICINOVA INC filed its 10-K report for the fiscal year ending December 3

Risk Profile

Risk Assessment: Of MNOV's 17 recent filings, 3 were flagged as high-risk, 6 as medium-risk, and 8 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Medicinova INC's most recent 10-Q filing (Nov 12, 2025):

• Revenue: $257,918
• Net Income: -$9,195,678
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $32,562,612
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Chief Executive Officer
• Chief Medical Officer
• Chief Financial Officer
• Yuichi Iwaki, M.D., Ph.D.
• Kirt W Shuldberg, Esq.
• John E. Maciejewski, Esq.

Industry Context

MediciNova operates in the biopharmaceutical industry, focusing on the development of novel therapeutics for serious diseases. This sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Success is often driven by innovation in drug discovery and successful clinical trial outcomes.

Top Tags

10-Q (4) · Clinical Trials (3) · quarterly-report (3) · material-definitive-agreement (2) · filing (2) · Biopharmaceutical (2) · Net Loss (2) · Cash Burn (2) · R&D Expenses (2) · Unmet Medical Needs (2)

Key Numbers

• SEC File Number: 001-33185 — Identifies the company's filing history with the SEC.
• IRS Employer Identification No.: 33-0927979 — Company's tax identification number.
• Net loss for Q3 2025: $3,050,373 — Increased from $2,852,179 in Q3 2024
• Net loss for nine months ended Sept 30, 2025: $9,195,678 — Increased from $8,234,897 in the prior year period
• Cash and cash equivalents as of Sept 30, 2025: $32,562,612 — Decreased from $40,359,738 at Dec 31, 2024
• Revenues for nine months ended Sept 30, 2025: $257,918 — Compared to $0 in the prior year period
• Total operating expenses for nine months ended Sept 30, 2025: $10,448,518 — Increased from $9,491,617 in the prior year period
• Shares of Common Stock outstanding: 49,046,246 — As of November 10, 2025
• Research, development and patents expense for Q3 2025: $1,582,975 — Decreased from $1,859,400 in Q3 2024
• Research, development and patents expense for nine months ended Sept 30, 2025: $5,611,429 — Increased from $5,287,318 in the prior year period
• Shares of Common Stock: 25,000,000 — Maximum shares offered by selling stockholder, representing potential dilution
• Aggregate Gross Proceeds: $30.0 million — Maximum amount MediciNova may receive from future sales to YA over 36 months
• Purchase Price Percentage: 97% — Price YA will pay for Advance Shares relative to the lowest of three daily VWAPs
• Last Reported Sale Price: $1.29 — MNOV's common stock price on Nasdaq Capital Market as of August 21, 2025
• Duration of Purchase Agreement: 36 months — Timeframe for MediciNova to sell shares to YA for up to $30.0 million

Related Companies

MEDX · MNVA · MDVN

Frequently Asked Questions